VEC-162 Study in Adult Patients With Primary Insomnia
NCT00548340
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
322
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Insomnia
Interventions
DRUG:
VEC-162 20 mg
DRUG:
Placebo
DRUG:
VEC-162 50 mg
Sponsor
Vanda Pharmaceuticals